GSK plc (LON:GSK) Receives GBX 1,805.83 Consensus PT from Analysts

GSK plc (LON:GSK) has received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is GBX 1,805.83 ($22.64).

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,850 ($23.19) price objective on shares of GSK in a research note on Tuesday, September 3rd. Berenberg Bank decreased their price target on GSK from GBX 1,820 ($22.82) to GBX 1,600 ($20.06) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, December 11th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, August 28th.

GSK Stock Performance

Shares of GSK opened at GBX 1,341.50 ($16.82) on Friday. The stock has a market capitalization of £54.73 billion, a price-to-earnings ratio of 1,187.17, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 12 month low of GBX 1,282.50 ($16.08) and a 12 month high of GBX 1,823.50 ($22.86). The firm has a fifty day simple moving average of GBX 1,384.87 and a 200 day simple moving average of GBX 1,504.20. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04.

GSK Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be paid a GBX 15 ($0.19) dividend. This represents a yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s dividend payout ratio (DPR) is presently 5,309.73%.

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction on Friday, December 20th. The stock was purchased at an average cost of GBX 1,315 ($16.48) per share, for a total transaction of £19,725 ($24,727.34). Insiders acquired 8,658 shares of company stock valued at $11,950,792 in the last quarter. 1.61% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.